| 產(chǎn)品名稱 | CCT 137690 |
| 產(chǎn)品貨號 | Axon 1836 CAS [1095382-05-0] MF C26H31BrN8OMW 551.48 Purity: 98% Moderately soluble in DMSO Description Potent and orally bioavailable Aurora kinase inhibitor, with IC50 values to be 15, 25 and 19 nM for Aurora A, B and C kinases respectively References Certificates Categories Extra info V Bavetsias et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J. Med. Chem. 2010, 53(14), 5213-5228.? ? A Faisal?et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol. Cancer Ther. 2011, 10(11), 2115-2123.? Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology Epigenetics EC 2.7.11.1 Aurora Aurora inhibitor (non-specific) Chemical name 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole Parent CAS No. [1095382-05-0] Order Size Unit Price Stock 10 mg €115.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
CCT 137690Axon 1836 CAS [1095382-05-0] MF C26H31BrN8O
Description
Potent and orally bioavailable Aurora kinase inhibitor, with IC50 values to be 15, 25 and 19 nM for Aurora A, B and C kinases respectively
Aurora inhibitor (non-specific)
Chemical name3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole Parent CAS No.[1095382-05-0] |
| 產(chǎn)品資料 |
